Results 191 to 200 of about 21,171,014 (388)
ABSTRACT Introduction To enhance the treatment quality in haemophilia centres (HC), the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research (GTH) started in 2017 the development of guidelines to define the structural and process quality of HC, essentially related to the EUHANET guidelines.
Hermann Eichler +18 more
wiley +1 more source
Severe haemophilia A with haemarthrosis improved on emicizumab: A case report
Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or
Wasifuddin Mustafa, Al-Gaithi Ibrahim
doaj +1 more source
Knowledge, attitude and practice of health care providers toward prescribing factor replacement at federally funded haemophilia treatment centres in the United States [PDF]
Maya Bloomberg +3 more
openalex +1 more source
Cardiovascular disease in hereditary haemophilia: The challenges of longevity [PDF]
Susan Shapiro +5 more
openalex +1 more source
Abstract Introduction Haemophilic knee arthropathy leads to a reduction in muscle mass and strength. Blood flow restriction (BFR) involves the application of a compressive cuff that enables strength training with reduced loads. Objective To evaluate safety as the primary outcome and the efficacy (muscle strength and activation, functional capacity and ...
Mar Villalón‐González +4 more
wiley +1 more source
ABSTRACT Introduction Despite therapeutic achievements in haemophilia care, there is still the need to monitor and define personal treatment outcomes and document results to achieve the best possible care. Hence, a need for unbiased, timely and comprehensive real‐world information exists to support informed shared decision‐making regarding treatment ...
Christoph Königs +9 more
wiley +1 more source
ABSTRACT Background Rotational thromboelastometry (ROTEM) aims to measure the coagulation potential in whole blood. Concizumab, an anti‐tissue factor pathway inhibitor (TFPI) antibody for prophylaxis in haemophilia, enhances tissue factor (TF)‐initiated coagulation by preventing inhibition of activated factor X (FXa), thus increasing thrombin ...
Hermann Eichler +9 more
wiley +1 more source
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen +5 more
wiley +1 more source

